Skip to content

LENSAR, Inc. LNSR Stock-Based Comp

Stock-Based Comp at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$300M+4.2%
Staar Surgical logo
Staar SurgicalSTAA
$4.82M-19.8%
Bausch + Lomb logo
Bausch + LombBLCO
$34M+21.4%
RxSight, Inc. logo
RxSight, Inc.RXST
$7.95M+11.3%
Schering-Plough logo
Schering-PloughSGP
$1.68M+386%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$2.22M+16.2%

Segments

By product

See full
Service$56K+75.0%

Other financials

Income statement

See full
Revenue$13.4M-5.2%
Gross profit$6.4M-10.4%
Operating income$2.2M+139%
Net income$36.3M+233%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$12.5M-36.1%
Total debt$7.6M+206%
Total equity$10.8M+149%
Total assets$66.2M-9.2%

Cash flow

See full
Operating cash flow-$4.3M+38.4%
CapEx$77.0K-31.9%
Free cash flow-

Valuation

See full
Market cap$70.13M-47.4%
Enterprise value$65.21M-49.0%
P/E2.4×
P/S1.2×-1.1×

Profitability

See full
Gross margin45.7%-2.1pp
Operating margin-28.7%+7.3pp
Net margin50.9%+30.7pp
FCF margin-26.6%

Returns & leverage

See full
Return on equity-164%-235pp
Debt / equity0.7×
Current ratio2.4×+0.6×

Where this comes from

Reported directly by LENSAR, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: LENSAR, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about LENSAR, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LENSAR, Inc.'s stock-based comp?
LENSAR, Inc. (LNSR) reported stock-based comp of $690K in Q1 2026.
How has LENSAR, Inc.'s stock-based comp changed year-over-year?
LENSAR, Inc.'s stock-based comp increased by 5.5% year-over-year, from $654K to $690K.
What is the long-term trend for LENSAR, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), LENSAR, Inc.'s stock-based comp has grown at a -17.7% compound annual growth rate (CAGR), from $6.87M to $3.14M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.